Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergeticsmitochondrial priming

Praveena S. Thiagarajan, Xiaoliang Wu, Wei Zhang, Ivy Shi, Rakesh Bagai, Patrick Leahy, Yan Feng, Martina Veigl, Daniel Lindner, David Danielpour, Lihong Yin, Rafael Rosell, Trever G. Bivona, Zhenfeng Zhang, Patrick C. Ma

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor progression on therapy. Here, we characterized a novel non-mutational early adaptive drug-escape in EGFR-mutant lung tumor cells only days after therapy initiation, that is MET-independent. The drug-escape cell states were analyzed by integrated transcriptomic and metabolomics profiling uncovering a central role for autocrine TGFβ2 in mediating cellular plasticity through profound cellular adaptive Omics reprogramming, with common mechanistic link to prosurvival mitochondrial priming. Cells undergoing early adaptive drug escape are in proliferative-metabolic quiescent, with enhanced EMT-ness and stem cell signaling, exhibiting global bioenergetics suppression including reverse Warburg, and are susceptible to glutamine deprivation and TGFβ2 inhibition. Our study further supports a preemptive therapeutic targeting of bioenergetics and mitochondrial priming to impact early drugescape emergence using EGFR precision inhibitor combined with broad BH3-mimetic to interrupt BCL-2/BCL-xL together, but not BCL-2 alone.

Original languageEnglish (US)
Pages (from-to)82013-82027
Number of pages15
JournalOncotarget
Volume7
Issue number50
DOIs
StatePublished - 2016

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergeticsmitochondrial priming'. Together they form a unique fingerprint.

  • Cite this

    Thiagarajan, P. S., Wu, X., Zhang, W., Shi, I., Bagai, R., Leahy, P., Feng, Y., Veigl, M., Lindner, D., Danielpour, D., Yin, L., Rosell, R., Bivona, T. G., Zhang, Z., & Ma, P. C. (2016). Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergeticsmitochondrial priming. Oncotarget, 7(50), 82013-82027. https://doi.org/10.18632/oncotarget.13307